EE05519B1 - im„„rne glkosleeritud lahustuva interleukiin 6retseptori/interleukiin 6 valk ja selle bioloogiliselt aktiivsed analoogid nende valmistamismeetodja kasutamine DNA j„rjestus DNA vektor transformeeritud imetajarakud ja farmatseutiline komposits - Google Patents

im„„rne glkosleeritud lahustuva interleukiin 6retseptori/interleukiin 6 valk ja selle bioloogiliselt aktiivsed analoogid nende valmistamismeetodja kasutamine DNA j„rjestus DNA vektor transformeeritud imetajarakud ja farmatseutiline komposits

Info

Publication number
EE05519B1
EE05519B1 EEP200000012A EEP200000012A EE05519B1 EE 05519 B1 EE05519 B1 EE 05519B1 EE P200000012 A EEP200000012 A EE P200000012A EE P200000012 A EEP200000012 A EE P200000012A EE 05519 B1 EE05519 B1 EE 05519B1
Authority
EE
Estonia
Prior art keywords
interleukin
immune
receptor
protein
pharmaceutical composition
Prior art date
Application number
EEP200000012A
Other languages
English (en)
Estonian (et)
Inventor
Michel@Revel
Judith@Chebath
Tsvee@Lapidot
Orit@@ollet
Original Assignee
Yeda@Research@and@Development@Co@@Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26323470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05519(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from IL12128497A external-priority patent/IL121284A0/xx
Application filed by Yeda@Research@and@Development@Co@@Ltd filed Critical Yeda@Research@and@Development@Co@@Ltd
Publication of EE200000012A publication Critical patent/EE200000012A/xx
Publication of EE05519B1 publication Critical patent/EE05519B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EEP200000012A 1997-07-10 1998-07-09 im„„rne glkosleeritud lahustuva interleukiin 6retseptori/interleukiin 6 valk ja selle bioloogiliselt aktiivsed analoogid nende valmistamismeetodja kasutamine DNA j„rjestus DNA vektor transformeeritud imetajarakud ja farmatseutiline komposits EE05519B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL12128497A IL121284A0 (en) 1997-07-10 1997-07-10 Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
IL12281897A IL122818A0 (en) 1997-07-10 1997-12-30 Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
PCT/IL1998/000321 WO1999002552A2 (en) 1997-07-10 1998-07-09 Chimeric interleukin-6 soluble receptor/ligand protein, analogs thereof and uses thereof

Publications (2)

Publication Number Publication Date
EE200000012A EE200000012A (et) 2000-08-15
EE05519B1 true EE05519B1 (et) 2012-02-15

Family

ID=26323470

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000012A EE05519B1 (et) 1997-07-10 1998-07-09 im„„rne glkosleeritud lahustuva interleukiin 6retseptori/interleukiin 6 valk ja selle bioloogiliselt aktiivsed analoogid nende valmistamismeetodja kasutamine DNA j„rjestus DNA vektor transformeeritud imetajarakud ja farmatseutiline komposits

Country Status (26)

Country Link
US (2) US7198781B1 (da)
EP (1) EP0991661B1 (da)
JP (1) JP4402288B2 (da)
KR (1) KR100505172B1 (da)
CN (1) CN1185348C (da)
AR (1) AR013201A1 (da)
AT (1) ATE342915T1 (da)
AU (1) AU758161B2 (da)
BG (1) BG64680B1 (da)
BR (1) BR9812096B1 (da)
CA (1) CA2295936C (da)
CY (1) CY1105895T1 (da)
CZ (1) CZ302488B6 (da)
DE (1) DE69836217T2 (da)
DK (1) DK0991661T3 (da)
EA (1) EA004793B1 (da)
EE (1) EE05519B1 (da)
ES (1) ES2271999T3 (da)
HU (1) HU225855B1 (da)
IL (2) IL122818A0 (da)
NO (1) NO327397B1 (da)
NZ (1) NZ502139A (da)
PL (1) PL199212B1 (da)
PT (1) PT991661E (da)
SK (1) SK287039B6 (da)
WO (1) WO1999002552A2 (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
US5919763A (en) * 1998-06-01 1999-07-06 Hadasit Medical Research Services And Development Company Ltd. IL-6/SIL-6R complex for promotion of liver functions
US20040170604A1 (en) 1998-07-06 2004-09-02 Tosoh Corporation IL-6 receptor IL-6 direct fusion protein
DE69941406D1 (de) * 1998-07-06 2009-10-22 Tosoh Corp IL-6 Rezeptor IL-6-gekoppeltes Fusionsprotein
KR100743640B1 (ko) * 1999-03-09 2007-07-27 지모제넥틱스, 인코포레이티드 신규한 사이토킨 ｚａｌｐｈａ 11 리간드
IL130586A0 (en) * 1999-06-21 2000-06-01 Yeda Res & Dev IL6RIL6 chimera for the treatment of demyelinating diseases
EP1290170A2 (en) 2000-06-16 2003-03-12 Asterion Limited Binding agents: chimeric ligand/receptor proteins
AU9184901A (en) * 2000-09-14 2002-03-26 Ares Trading Sa Use of il-6r/il-6 chimera in huntington's disease
DE10106827A1 (de) * 2001-02-14 2002-09-05 Stefan Rose-John Verwendung eines Konjugats aus Interleukin-6(IL-6) und seinem Rezeptor zur Induktion der zellulären Expression des Stammzellfaktors (SCF) und von Flat-3-Ligand (Flt-3L)
DE10107737A1 (de) * 2001-02-16 2002-09-05 S Rose John Christian Albrecht Verwendung eines Konjugats aus IL-6 und einem IL-6 Rezeptor zur Tumortherapie
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
GB0119015D0 (en) * 2001-08-03 2001-09-26 Univ Cardiff A fusion protein
GB2384001B (en) * 2001-12-14 2004-02-04 Asterion Ltd Chimeric growth hormone-growth hormone receptor proteins
IL147412A0 (en) 2001-12-31 2002-08-14 Yeda Res & Dev The use of il6r/il6 chimera in nerve cell regeneration
AU2003223089A1 (en) * 2002-04-29 2003-11-17 Hadasit Medical Research Services And Development Company Ltd. Compositions and methods for treating cancer with an oncolytic viral agent
WO2004069173A2 (en) 2003-01-31 2004-08-19 The Trustees Of The University Of Pennsylvania Methods for modulating an inflammatory response
FR2850621B1 (fr) * 2003-02-04 2006-12-08 Journee Paul Connecteur reliant un bras d'essuie-glace a un balai d'essuyage, qui comporte deux languettes pour le verrouillage transversal de bras d'essuie-glace
DE10321317A1 (de) * 2003-05-13 2004-12-23 Christian-Albrechts-Universität Zu Kiel Verfahren zum Nachweis des funktionellen IL-6/ sIL-6-Rezeptor-Komplexes und Test-Kit zur Durchführung dieses Verfahrens
IL157309A0 (en) * 2003-08-07 2004-02-19 Applied Research Systems Method for the purification of a non-immunoglobulin protein
IL159558A0 (en) * 2003-12-24 2004-06-01 Applied Research Systems Use of il-6 in liver injury
IL161673A0 (en) 2004-04-29 2004-09-27 Applied Research Systems Compositions and methods for therapy of chemotherapy-induced neuropathy
IL161672A0 (en) 2004-04-29 2004-09-27 Yeda Res & Dev Compositions and methods for therapy of chemotherapy-induced neuropathy
AU2012261726B2 (en) * 2005-08-29 2015-03-12 Technion Research & Development Foundation Ltd. Media for Culturing Stem Cells
EP1962719A4 (en) 2005-08-29 2011-05-04 Technion Res And Dev Of Foundation Ltd MEDIA FOR BREEDING STEM CELLS
EP1777294A1 (en) * 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
JP2009543579A (ja) * 2006-07-19 2009-12-10 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗炎症反応のための標的としてのＷＳＸ−１／ｐ２８
DK3441459T3 (da) * 2006-08-02 2021-06-07 Technion Res & Dev Foundation Fremgangsmåder til ekspansion af embryonale stamceller i en suspensionskultur
EP2097517B1 (en) 2006-10-16 2014-06-04 Genelux Corporation Recombinant Lister strain vaccinia virus encoding an anti-VEGF single chain antibody
CA2690627C (en) * 2007-06-15 2014-12-02 Genelux Corporation Microorganisms for imaging and/or treatment of tumors
GB0715216D0 (en) * 2007-08-03 2007-09-12 Asterion Ltd Leptin
EP2185583A2 (en) * 2007-08-03 2010-05-19 Asterion Limited Granulocyte colony stimulating factor
MX2011000071A (es) * 2008-07-02 2011-05-03 Emergent Product Dev Seattle Inmunoterapeuticos de interleucina-6 (il6).
NZ590667A (en) * 2008-07-02 2013-01-25 Emergent Product Dev Seattle Tgf-b antagonist multi-target binding proteins
EP2387415A1 (en) 2009-01-16 2011-11-23 AGIRx Limited Vaccine compositions
US9018010B2 (en) 2009-11-12 2015-04-28 Technion Research & Development Foundation Limited Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
WO2011079308A2 (en) 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
JP6283223B2 (ja) 2010-09-07 2018-02-21 テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド 多能性幹細胞を培養するための新規な方法および培養培地
EP2832856A4 (en) 2012-03-29 2016-01-27 Chugai Pharmaceutical Co Ltd ANTI-LAMP5 ANTIBODIES AND USE THEREOF
US11401312B2 (en) 2013-04-19 2022-08-02 Cytune Pharma Cytokine derived treatment with reduced vascular leak syndrome
EP3033415A4 (en) * 2013-08-12 2017-01-11 Merck Sharp & Dohme Corp. Methods and compositions for co-expression of polypeptides of interest and il6
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
CN104826093A (zh) * 2015-04-16 2015-08-12 刘永庆 用于治疗慢性传染性肝病的Th2免疫反应拮抗剂及卵黄抗体
CN108030916A (zh) * 2015-07-03 2018-05-15 刘永庆 防治肿瘤和/或慢性结核病的Th2免疫反应抑制剂及其应用
US20240269236A1 (en) 2021-06-04 2024-08-15 Sonnet BioTherapeutics, Inc. Methods of treating age-related frailty with interleukin-6
CN116064563B (zh) * 2022-11-04 2025-11-11 广州达安基因股份有限公司 白细胞介素-6截短体的制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216128A (en) * 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
IL99803A (en) * 1991-10-20 1997-02-18 Yeda Res & Dev Pharmaceutical compositions comprising interleukin-6 for the treatment of chronic lymphocytic leukemia and B-cell lymphomas
PL190445B1 (pl) * 1995-05-15 2005-12-30 Akademia Medyczna Im K Marcink Genetyczna szczepionka przeciwrakowa
DE19608813C2 (de) * 1996-03-07 1998-07-02 Angewandte Gentechnologie Syst Konjugat zur Beeinflussung von Wechselwirkungen zwischen Proteinen
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
NZ504771A (en) * 1997-12-19 2002-09-27 Applied Research Systems IFNAR2/ INFcomplex for prolonging the in vivo effects of type I interferon (INF)

Also Published As

Publication number Publication date
PL199212B1 (pl) 2008-08-29
DE69836217T2 (de) 2007-08-23
EP0991661A2 (en) 2000-04-12
BG64680B1 (bg) 2005-11-30
BG104070A (en) 2000-11-30
HU225855B1 (en) 2007-11-28
CY1105895T1 (el) 2011-02-02
DK0991661T3 (da) 2007-02-05
BR9812096B1 (pt) 2011-09-06
ES2271999T3 (es) 2007-04-16
ATE342915T1 (de) 2006-11-15
IL133972A (en) 2015-07-30
US7374912B2 (en) 2008-05-20
EA200000109A1 (ru) 2000-08-28
PL338002A1 (en) 2000-09-25
US20070172455A1 (en) 2007-07-26
HUP0002426A3 (en) 2003-01-28
EA004793B1 (ru) 2004-08-26
EP0991661B1 (en) 2006-10-18
HK1031895A1 (en) 2001-06-29
IL122818A0 (en) 1998-08-16
BR9812096A (pt) 2000-07-18
US7198781B1 (en) 2007-04-03
KR20010021522A (ko) 2001-03-15
DE69836217D1 (de) 2006-11-30
AU8127198A (en) 1999-02-08
WO1999002552A3 (en) 1999-04-01
CA2295936C (en) 2009-05-26
CZ302488B6 (cs) 2011-06-15
SK287039B6 (sk) 2009-10-07
CN1269835A (zh) 2000-10-11
KR100505172B1 (ko) 2005-08-03
CZ200075A3 (cs) 2000-08-16
AU758161B2 (en) 2003-03-20
JP4402288B2 (ja) 2010-01-20
JP2001509371A (ja) 2001-07-24
SK62000A3 (en) 2000-07-11
CA2295936A1 (en) 1999-01-21
NO20000086D0 (no) 2000-01-07
HUP0002426A2 (hu) 2000-11-28
PT991661E (pt) 2007-01-31
WO1999002552A2 (en) 1999-01-21
NZ502139A (en) 2002-03-28
EE200000012A (et) 2000-08-15
AR013201A1 (es) 2000-12-13
NO20000086L (no) 2000-03-08
NO327397B1 (no) 2009-06-22
CN1185348C (zh) 2005-01-19

Similar Documents

Publication Publication Date Title
EE05519B1 (et) im„„rne glkosleeritud lahustuva interleukiin 6retseptori/interleukiin 6 valk ja selle bioloogiliselt aktiivsed analoogid nende valmistamismeetodja kasutamine DNA j„rjestus DNA vektor transformeeritud imetajarakud ja farmatseutiline komposits
BR9507678A (pt) Construção de dna vetor de expressão recombinante célula proceso para produzir uma enzima enzima preparação de enzima uso da enzima e cultura
PL314051A1 (en) Recombined obesity proteins (ob), fusion proteins, expression vectors, sequential dnas, transformed e, collie cells, method of obtaining recombined human or mouse's obesity protein and pharmaceutic composition
EP1225225A3 (en) Osteogenic devices
AR017866A1 (es) Metodo para incrementar las inmunorespuestas de vacunas de acidos nucleicos, composiciones farmaceuticas de aplicacion en dicho metodo, procedimientopara preparar dichas composiciones y vacunas utilizadas en dicho metodo.
EP1686172A3 (en) Myocardial grafts and cellular compositions useful for same
ATE327254T1 (de) Interferon-beta fusionsproteine und deren verwendungen
MX9502034A (es) Formulacion estable, liofilizada, que comprende una proteina y equipo de dosificacion.
ES2181281T3 (es) Formulaciones liquidas de interferon beta.
GB9720054D0 (en) Biological products
DK0506884T3 (da) Fremgangsmåde til afgivelse af molekyler til eukaryotiske celler
AU2087401A (en) Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
IL112316A0 (en) T cell antigen receptor v region proteins and methods of preparation thereof
FR2763943B1 (fr) Composes, leur preparation et leur utilisation pour le transfert d'acides nucleiques dans les cellules
WO1997031934A3 (de) Neue metabolisierbare lipopolyamine, deren darstellung und anwendung
EP0540645A4 (en) Methods of use of bovine respiratory syncytial virus recombinant dna, proteins vaccines, antibodies, and transformed cells
ES2167939T3 (es) Nuevas poliaminas, su preparacion y usos.
AU7758598A (en) Stable pharmaceutical administration forms of peptides, proteins and nucleic acids
BR9604938A (pt) Vírus recombinante deficiente utilização deste vírus composição farmacêutica e célula de mamífero
NO20000990L (no) Fremgangsmõter og sammensetninger for behandlinger som anvender gener som koder for utskilte proteiner sõ som interferon <beta>
IL90356A0 (en) Amphiphilic peptides and pharmaceutical compositions containing them
FR2625099B1 (fr) Proteines et leur procede de preparation, sequences d'adn, anticorps et leur application, poxvirus, cellules transformees ou infectees et compositions pharmaceutiques utiles dans la prevention de la toxoplasmose
DK0805204T3 (da) Bitestikel - specifikt receptorprotein og anvendelse heraf
FI915654A0 (fi) Somatotropiner med alterneringar i alfahelixregionen 1 och kombinationer med andra mutationer.
DK292584D0 (da) Biologisk aktive konjugater, deres fremstilling og anvendelse

Legal Events

Date Code Title Description
MM4A Lapsed by not paying the annual fees

Effective date: 20160709